Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
03/27/2020 03/30/2020 03/31/2020 04/01/2020 04/02/2020 Date
4.778(c) 5.5(c) 5.93(c) 5.55(c) 5.68(c) Last
372 173 1 894 590 847 786 307 973 291 018 Volume
+2.75% +15.11% +7.82% -6.41% +2.34% Change
More quotes
Financials (EUR)
Sales 2019 90,6 M
EBIT 2019 -16,3 M
Net income 2019 -9,95 M
Finance 2019 49,3 M
Yield 2019 -
Sales 2020 101 M
EBIT 2020 -59,9 M
Net income 2020 -48,3 M
Finance 2020 92,5 M
Yield 2020 -
P/E ratio 2019 -41,1x
P/E ratio 2020 -114x
EV / Sales2019 4,40x
EV / Sales2020 3,52x
Capitalization 448 M
More Financials
Company
Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune... 
More about the company
Surperformance© ratings of Innate Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on INNATE PHARMA
03/10INNATE PHARMA : First patient dosed in IPH5201 Phase I clinical trial in advance..
AQ
03/10First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumor..
GL
03/10INNATE PHARMA : reports full year 2019 financial results and business update
GL
03/10INNATE PHARMA : Annual results
CO
03/10INNATE PHARMA : Slide show results
CO
01/31INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/29INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
01/29Rosen Law Firm Announces Investigation of Securities Claims Against Innate Ph..
BU
01/14INNATE PHARMA : SA - French regulatory agency agrees lacutamab TELLOMAK trial ca..
AQ
01/13INNATE PHARMA : French regulatory agency agrees lacutamab TELLOMAK trial can res..
GL
01/13French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitme..
GL
01/09Tesla vindicated, Apple enjoys success in China, Boeing’s troubles continue…
01/09INNATE PHARMA : Provides update from regulatory agencies on lacutamab tellomak t..
GL
01/09Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK ..
GL
01/03INNATE PHARMA : SA - The European Medicines Agency accepts the regulatory submis..
AQ
More news
News in other languages on INNATE PHARMA
03/30INNATE PHARMA : parmi les plus fortes hausses du SRD à la clôture du lundi 30 ma..
03/30INNATE PHARMA : plus forte hausse du SRD à la mi-séance du lundi 30 mars 2020
03/13INNATE PHARMA : plus forte baisse du marché SRD à la clôture du vendredi 13 mars..
03/10STOCK MARKET PARIS : Un rebond fragile après la débâcle
03/10Les valeurs à suivre aujourd'hui à la Bourse de Paris Mardi 10 mars 2020
More news
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | IPH | FR0010331421 | MarketScreener
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 11,92  €
Last Close Price 5,68  €
Spread / Highest target 175%
Spread / Average Target 110%
Spread / Lowest Target 58,5%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Pierre F. Dodion Chief Medical Officer & Executive VP
Sector and Competitors